Loading company…
Cambridge-based Repertoire Immune Medicines develops immune therapies for cancer and autoimmune disease using its DECODE platform.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Repertoire Immune Medicines develops immune therapies for solid and hematological cancers and autoimmune conditions. Its proprietary DECODE platform maps immune synapses and T cell codes to design programmable immune medicines. Revenue comes from partnerships with biopharmaceutical firms and research institutions, which may include milestone payments and royalties. In April 2021 it raised USD 189.00 mn in Series B funding from investors including Carlyle Group and Flagship Pioneering, at a current valuation of USD 474.32 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in